In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase

Meng,Fankai; Zeng,Wen; Huang,Lifang; Qin,Shuang; Miao,Ningning; Sun,Hanying; Li,Chunrui

doi:10.3892/ol.2014.1780

In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase

Authors:
- Fankai Meng
- Wen Zeng
- Lifang Huang
- Shuang Qin
- Ningning Miao
- Hanying Sun
- Chunrui Li
View Affiliations

Affiliations: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: January 2, 2014 https://doi.org/10.3892/ol.2014.1780
Pages: 791-796

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Imatinib is a tailored drug for the treatment of chronic myeloid leukemia (CML), and has substantial activity and a favorable safety profile when used as a single agent in patients with CML in myeloid blast crisis. The megakaryocytic blast crisis in CML occurs rarely and carries a poor prognosis. The aim of the present study was to investigate the effects of imatinib on cluster of differentiation (CD)34+ cells from patients with CML in the megakaryocytic crisis phase. Bone marrow mononuclear cells (BMNCs) were isolated from patients with CML in the megakaryocytic crisis phase. CD34+ cells were selected from BMNCs by positive immunomagnetic column separation. Imatinib significantly induced G1 arrest, reduced the phosphorylation of cyclin‑dependent kinase 1 and retinoblastoma proteins and inhibited the proliferation of CD34+ cells from patients with CML in the megakaryocytic crisis phase. Annexin V/propidium iodide and caspase‑3 activity showed that imatinib induced apoptosis. Western blot analysis and protein tyrosine kinase activity assays showed that imatinib inhibited BCR‑ABL protein tyrosine kinase activity. The in vitro data thus markedly indicate a potential clinical application of imatinib for patients with CML in the megakaryocytic crisis phase.

View Figures

View References

1	Hehlmann R: How I treat CML blast crisis. Blood. 120:737–747. 2012. View Article : Google Scholar : PubMed/NCBI
2	Druker BJ, Guilhot F, O’Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 355:2408–2417. 2006.PubMed/NCBI
3	Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 349:1423–1432. 2003. View Article : Google Scholar
4	Randolph TR: Chronic myelocytic leukemia - Part II: Approaches to and molecular monitoring of therapy. Clin Lab Sci. 18:49–56. 2005.PubMed/NCBI
5	Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:561–566. 1996. View Article : Google Scholar : PubMed/NCBI
6	Deininger MW, Goldman JM, Lydon N and Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 90:3691–3698. 1997.PubMed/NCBI
7	Gambacorti-Passerini C, le Coutre P, Mologni L, et al: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL⁺ leukemic cells and induces apoptosis. Blood Cells Mol Dis. 23:380–394. 1997. View Article : Google Scholar : PubMed/NCBI
8	Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:1031–1037. 2001. View Article : Google Scholar : PubMed/NCBI
9	Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 344:1038–1042. 2001. View Article : Google Scholar
10	Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:3530–3539. 2002. View Article : Google Scholar
11	Pelloso LA, Baiocchi OC, Chauffaille ML, Yamamoto M, Hungria VT and Bordin JO: Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia. Eur J Haematol. 69:58–61. 2002. View Article : Google Scholar : PubMed/NCBI
12	Campiotti L, Grandi AM, Biotti MG, Ultori C, Solbiati F, Codari R and Venco A: Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia. Am J Hematol. 82:231–233. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wu CD, Medeiros LJ, Miranda RN, Mark HF and Rintels P: Chronic myeloid leukemia manifested during megakaryoblastic crisis. South Med J. 89:422–427. 1996. View Article : Google Scholar : PubMed/NCBI
14	Takahashi N, Miura I, Saitoh K and Miura AB: Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood. 92:4758–4763. 1998.
15	Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–3849. 1999.
16	Garand R and Robillard N: Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. Hematol Cell Ther. 38:471–486. 1996. View Article : Google Scholar
17	Yin T, Wu YL, Sun HP, et al: Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 104:4219–4225. 2004. View Article : Google Scholar : PubMed/NCBI
18	Kim DH, Lee ST, Won HH, et al: A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood. 117:6906–6911. 2011. View Article : Google Scholar
19	Colla S, Sammarelli G, Crugnola M, et al: Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. Eur J Haematol. 72:361–365. 2004. View Article : Google Scholar
20	Westfall DE, Zhang L, Song S and Lee S: Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis. Arch Pathol Lab Med. 132:1021–1025. 2008.PubMed/NCBI
21	Nath N, Wang S, Betts V, Knudsen E and Chellappan S: Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene. 22:5986–5994. 2003. View Article : Google Scholar : PubMed/NCBI
22	Jackman M, Lindon C, Nigg EA and Pines J: Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol. 5:143–148. 2003. View Article : Google Scholar : PubMed/NCBI
23	Kim BS, Bae E, Kim YJ, et al: Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia. Anticancer Drugs. 18:641–647. 2007. View Article : Google Scholar : PubMed/NCBI
24	Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S and Bhalla KN: CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 96:2246–2253. 2000.
25	Kawano T, Horiguchi-Yamada J, Iwase S, Akiyama M, Furukawa Y, Kan Y and Yamada H: Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res. 24:2705–2712. 2004.